The use of Goserelin in the management of endometriosis

In: Obstetrics and Gynaecology Forum · 2009 · vol. 19(1) · doi:10.4314/ogf.v19i1.43679 · W2042355396
article OA: closed CC0 ⤵ 1 in-corpus citation
Full text JSON View on OpenAlex View at publisher

Abstract

Zoladex (Goserelin acetate implant) contains a synthetic decapeptide analogue of luteinising hormone releasing (GnRH) agonist analogue. Zoladex is designed for subcutaneous injection (sterile biodegradable productequivalent to 3.6mg Goserelin)
Full text 508 characters · extracted from oa-doi-fallback · click to expand
Main Article Content The use of Goserelin in the management of endometriosis Abstract equivalent to 3.6mg Goserelin) Journal / Obstetrics and Gynaecology Forum / Vol. 19 No. 1 (2009) / Articles Zoladex (Goserelin acetate implant) contains a synthetic decapeptide analogue of luteinising hormone releasing (GnRH) agonist analogue. Zoladex is designed for subcutaneous injection (sterile biodegradable product equivalent to 3.6mg Goserelin) equivalent to 3.6mg Goserelin) eISSN: 1027-9148 print ISSN: 1029-1962

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-08-12T06:43:03.944938+00:00
License: CC0 · commercial use OK